You asked What percent of patients on Gleevec develop a mutation or resistance? 10%? Less than 10%? Answer: More than 10% Eventually, 30% of pts become resistant to gleevec(about half from mutations) and 50% become resistant to sprycel and/or tasigna. It's a significant market whether AP534 eventually gets approved as first line treatment or not.